Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey

Table 4 Demographic, clinical and treatment characteristics by states in Brazil (continuation of Table 3)

Characteristics	Piauí	Amazonas	Pará	Alagoas	Rio Grande do Norte	Mato Grosso	Paraíba	Acre	Sergipe	Mato Grosso do Sul	Tocantins	Rondônia	Roraima	Amapá
	n = 41 (%)	n = 38 (%)	n = 32 (%)	n = 31 (%)	n = 25 (%)	n = 22 (%)	n = 18 (%)	n = 16 (%)	n = 13 (%)	n = 12 (%)	n = 7 (%)	n = 6 (%)	n = 6 (%)	n = 3 (%)
Clinical risk factors
Age ≥ 70 yr	-	-	-	-	-	-	3 (16.7)	2 (12.5)	-	1 (8.3)	-	-	-	-
Hypertension	5 (12.2)	4 (10.5)	1 (3.1)	4 (12.9)	1 (4.0)	2 (9.1)	5 (27.8)	3 (18.8)	1 (7.7)	3 (25.0)	-	3 (50.0)	3 (50.0)	1 (33.3)
Diabetes	-	2 (5.3)	-	1 (3.2)	-	-	1 (5.6)	2 (12.5)	-	1 (8.3)	-	-	-	-
Cardiovascular diseases	1 (2.4)	-	-	-	1 (4.0)	1 (4.5)	-	1 (6.3)	-	2 (16.7)	-	-	1 (16.7)	-
Liver diseases	2 (4.9)	2 (5.3)	5 (15.6)	1 (3.2)	1 (4.0)	2 (9.1)	2 (11.1)	-	-	-	-	-	-	-
Abdominal surgery for IBD (< 30 d)	2 (4.9)	4 (10.5)	2 (6.3)	1 (3.2)	-	-	-	1 (6.3)	-	-	-	-	-	-
Overall IBD medications
No medication	5 (12.2)	5 (13.2)	5 (15.6)	1 (3.2)	-	2 (9.1)	-	2 (12.5)	1 (7.7)	3 (25.0)	2 (28.6)	1 (16.7)	3 (50.0)	-
Oral steroids	8 (19.5)	7 (18.4)	6 (18.8)	-	3 (12.0)	5 (22.7)	3 (16.7)	3 (18.8)	1 (7.7)	1 (8.3)	-	1 (16.7)	-	-
5-ASA	11 (26.8)	15 (39.5)	21 (65.6)	8 (25.8)	6 (24.0)	12 (54.5)	10 (55.6)	4 (25.0)	7 (53.8)	3 (25.0)	2 (28.6)	4 (66.7)	2 (33.3)	1 (33.3)
AZA/6-MP/MTX	9 (22.0)	11 (28.9)	7 (21.9)	13 (41.9)	5 (20.0)	5 (22.7)	7 (38.9)	4 (25.0)	4 (30.8)	2 (16.7)	3 (42.9)	1 (16.7)	-	2 (66.7)
Biologics	20 (48.8)	19 (50.0)	6 (18.8)	19 (61.3)	21 (84.0)	5 (22.7)	8 (44.4)	6 (37.5)	7 (53.8)	6 (50.0)	2 (28.6)	1 (16.7)	1 (16.7)	1 (33.3)
Therapeutic regimen
Oral steroid monotherapy1	5 (12.2)	-	1 (3.1)	-	-	-	-	2 (12.5)	-	-	-	-	-	-
5-ASA monotherapy1	9 (22.0)	9 (23.7)	15 (46.9)	4 (12.9)	3 (12.0)	10 (45.5)	8 (44.4)	4 (25.0)	3 (23.1)	2 (16.7)	1 (14.3)	4 (66.7)	2 (33.3)	1 (33.3)
5-ASA + oral steroids2	-	3 (33.3)	4 (26.7)	-	-	4 (40.0)	1 (12.5)	-	-	-	-	1 (25.0)	-	-
AZA/6-MP/MTX monotherapy1	2 (4.9)	5 (13.2)	5 (15.6)	7 (22.6)	1 (4.0)	5 (22.7)	2 (11.1)	2 (12.5)	2 (15.4)	1 (8.3)	2 (28.6)	-	-	1 (33.3)
AZA/6-MP/MTX + oral steroids2	-	1 (20.0)	-	-	-	1 (20.0)	-	1 (50.0)	-	1 (100)	-	-	-	-
Biologic monotherapy1	13 (31.7)	13 (34.2)	4 (12.5)	13 (41.9)	17 (68.0)	5 (22.7)	3 (16.7)	4 (25.0)	5 (38.5)	5 (41.7)	1 (14.3)	-	1 (16.7)	-
Biologic + oral steroids2	1 (7.7)	3 (23.1)	-	-	1 (5.9)	-	-	-	1 (20.0)	-	-	-	-	-
Combo therapy3	7 (17.1)	6 (15.8)	2 (6.3)	6 (19.4)	4 (16.0)	-	5 (27.8)	2 (12.5)	2 (15.4)	1 (8.3)	1 (14.3)	1 (16.7)	-	1 (33.3)
Combo therapy3 + oral steroids2	2 (28.6)	-	1 (50.0)	-	2 (50.0)	-	2 (40.0)	-	-	-	-	-	-	-
Risk classification
Low	10 (24.4)	7 (18.4)	13 (40.6)	4 (12.9)	3 (12.0)	9 (40.9)	6 (33.3)	4 (25.0)	4 (30.8)	3 (25.0)	2 (28.6)	3 (50.0)	2 (33.3)	-
Medium	24 (58.5)	22 (57.9)	14 (43.8)	22 (71.0)	16 (64.0)	11 (50.0)	4 (22.2)	6 (37.5)	7 (53.8)	7 (58.3)	4 (57.1)	2 (33.3)	3 (50.0)	3 (100)
High	7 (17.1)	9 (23.7)	5 (15.6)	5 (16.1)	6 (24.0)	2 (9.1)	8 (44.4)	6 (37.5)	2 (15.4)	2 (16.7)	1 (14.3)	1 (16.7)	1 (16.7)	-

¹Monotherapy indicates no concomitant biologics or aminosalicylates/6-mercaptopurine/methotrexate.

²These subcategories represent the frequency of patients in each therapeutic regimen requiring oral steroids.

³Combo therapy refers to biologics plus aminosalicylates/6-mercaptopurine/methotrexate.

5-ASA: Aminosalicylates; AZA: Azathioprine; 6-MP: 6-Mercaptopurine; MTX: Methotrexate; IBD: Inflammatory bowel disease.